Devil's Claw.
May offer mild relief for joint discomfort. A traditional herb thought to reduce mild joint pain and stiffness. It contains compounds that may have some anti-inflammatory properties.
Reviewed March 2026
- Category
- Herb
- Also filed under
- Joint healthPain relief
What Devil's Claw is, and what it does.
- Does it work
- Maybe. The evidence is mixed. Some human trials show a benefit for joint discomfort, others don't. It's not a replacement for proven treatments.
- How much to take
- Look for a standardized extract providing 50-100mg of harpagoside daily. This usually means taking 500-1000mg of the total extract, split into two doses.
- Time to feel it
- The bitterness is immediate. Joint comfort measures in trials move over four to eight weeks of daily use, so the useful read is at the end of that stretch.
- The first dose
- Nothing. This needs to build up in your system. Don't expect any relief for at least a couple of weeks.
- With regular use
- After a month or two, some people notice a modest improvement in mobility and less day-to-day joint achiness. If you feel nothing after 6 weeks, it's probably not for you.
- How well tolerated
- Generally well tolerated, but has a few specific warnings. Can cause stomach upset. Avoid if you have ulcers, gallstones, or take blood thinners.
- How it feels
- A gradual, mild easing of joint discomfort. Not a 'wow' effect. More of a background helper than a potent pain reliever.
- The overlooked benefit
- The bitter iridoids that mark this extract also carry its older use as a digestive bitter, raising gastric secretion, which is why it is conventionally taken with food.
500 to 750mg a day is where Devil's Claw works.
Source: Gagnier et al. 2004 Cochrane Review. Brien et al. 2006 BMC Complement Altern Med.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
While some studies suggest benefits for joint health, the overall evidence base is moderate. More research is needed to confirm these effects and determine optimal dosages.
- Joint comfort and mobilityRandomised trial
- Everyday lower back comfortRandomised trial
- Physical function scores in comfort trialsRandomised trial
- Healthy inflammatory responseIn vitro study
- Digestive bitter and appetite stimulationNarrative review
- Antioxidant activity of harpagosideIn vitro study
Questions people ask about Devil's Claw.
- Is this better than ibuprofen?
- No. It's much milder and slower. Ibuprofen is for acute pain; this is for chronic, low-grade discomfort.
- How long until I know if it's working?
- Give it at least 4-6 weeks of consistent use. If you feel zero difference by then, it's likely not going to work for you.
- Can I take it with glucosamine?
- Yes, they don't interact. Many joint supplements combine them, though the evidence for that combo isn't strong.
- Why is it called Devil's Claw?
- The plant's fruit has large, claw-like hooks. Looks pretty menacing.
- Does it work for back pain?
- Some of the research suggests it might help with low back pain, but the evidence is a bit stronger for hip and knee discomfort.
- What are the side effects?
- Stomach upset or diarrhea are the most common ones. Taking it with food usually helps.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Devil's claw harpagosides act mainly on cyclooxygenase-driven prostaglandin signaling while boswellic acids work largely on the 5-lipoxygenase arm, so the two reach different branches of the body's normal inflammatory response. That complementary coverage is why they are a long-standing pairing in joint-comfort formulas.
Curcumin and devil's claw both quiet NF-kB and cytokine signaling that governs the body's normal inflammatory tone, reaching the same process through partly different molecular steps. Formulators combine them so the effect on joint and connective-tissue comfort is broadened rather than duplicated.
Ginger gingerols and devil's claw both act on the eicosanoid pathways that also regulate normal platelet aggregation, so stacking them can add up more than either alone. Worth spacing or moderating when combined, especially alongside anything else that affects normal clotting.
White willow salicin converts to salicylate that acts on the same prostaglandin-forming COX enzymes devil's claw works on, so the two press on one pathway together. That overlap can compound effects on the stomach lining and on normal clotting, so combine them cautiously.
Harpagosides act on eicosanoid signalling while MSM contributes sulfur to matrix sulfation and glutathione turnover. The two sit on different mechanisms in the same joint comfort stack.
Devil's claw works on signalling that governs joint comfort, whereas glucosamine supplies amino sugar substrate for cartilage matrix. Signalling and substrate are additive, not redundant.
Chondroitin holds water in the cartilage matrix and moderates degradative enzyme activity, a structural lever distinct from the iridoid glycosides in devil's claw. Joint blends routinely carry both.
Bromelain is a proteolytic enzyme that acts on fibrin and kinin handling, a separate route into normal tissue comfort. It has been paired with devil's claw in joint formulas for decades.
AKBA acts mainly on the 5-lipoxygenase branch of eicosanoid production, while harpagoside is described on the cyclooxygenase and cytokine side. Covering both branches is the reason the pair is a formulation staple.
Cat's claw alkaloids act on NF-kB driven cytokine signalling, upstream of the eicosanoid steps devil's claw is associated with. The two are combined to hit sequential points in the same cascade.
Collagen peptides raise circulating glycine, proline and hydroxyproline for matrix rebuilding, which devil's claw does not supply at all. Comfort signalling plus matrix substrate is the usual pairing logic.
Piperine slows intestinal and hepatic phase-II conjugation and P-glycoprotein efflux, which raises systemic exposure to co-taken plant constituents. Harpagoside is a glycoside subject to that same first-pass handling.
Long-chain omega-3s shift thromboxane production and lengthen normal platelet aggregation, and devil's claw has reported antiplatelet activity of its own. The two together push normal clotting further than either alone.
Devil's claw is a bitter that stimulates gastric secretion, and betaine HCl adds free acid directly. Stacked at full doses they can make the stomach noticeably more acidic than intended, so they are usually staggered.
Prolyl and lysyl hydroxylase require ascorbate to hydroxylate collagen chains, which is what lets the triple helix hold together. Devil's claw is used in joint comfort blends that also carry collagen or connective-tissue ingredients, and those depend on that hydroxylation step. The vitamin does not change devil's claw pharmacology; it supports the tissue side of the same formula.
Devil's claw root is a classic bitter, and its traditional digestive use runs through bitter receptors and a reflex rise in gastric secretion. Alkalising agents raise gastric pH and blunt exactly that response. Taking an antacid alongside works against the bitter action, though it does not affect the harpagoside absorbed for joint use.
Charcoal adsorbs small organic molecules non-selectively in the gut, and iridoid glycosides such as harpagoside are within that range. Co-timed dosing lowers how much reaches the circulation. Spacing the two by a few hours is the standard handling.
Pine bark procyanidins are studied against inflammatory and oxidative markers relevant to joint comfort during activity. Devil's claw harpagosides are studied against the same marker family. The pairing is common in formulation and has not been isolated in a combination trial, so it rests on mechanism.
Grape seed procyanidins and devil's claw phenylethanoids both cycle through oxidised and reduced states and can regenerate one another in solution. That chemistry is well described in vitro. Whether it changes a measurable outcome after ingestion has not been shown.
Astaxanthin sits in the lipid phase of membranes, while devil's claw constituents are water-soluble glycosides. Antioxidant networks depend on both phases being covered, which is the argument for combining them. Read this as mechanistic rather than clinical.
Hyaluronic acid is a normal constituent of synovial fluid and contributes to its viscosity. Devil's claw is used for joint comfort and mobility during activity through a different, signalling-level route. A blend covers structure and comfort separately rather than reinforcing one mechanism.
Magnesium is required for normal muscle relaxation and neuromuscular signalling, which is adjacent to but distinct from joint comfort. Blends aimed at movement often carry both for that reason. No trial has measured them together.
Devil's claw is listed in European monographs for loss of appetite and mild digestive discomfort on the strength of its bitter iridoids. Supplemental proteases and lipases act downstream on the meal itself. The two sit at different stages of the same meal, which is why bitters and enzymes are conventionally packed together.
Ginkgolides antagonise platelet-activating factor, a well-described action. Devil's claw has been reported in case-level literature to be co-implicated in bleeding events, though the mechanism is not established. Where both appear in one regimen, the additive direction is worth flagging rather than assumed absent.
Talk to a doctor before taking Devil's Claw if any of these apply to you: Pregnancy, Breastfeeding, Gallstones, Stomach ulcers, Blood thinners. These are flags to check first, not effects Devil's Claw is known to cause.
Not medical advice. Show the label to your pharmacist.What Devil's Claw actually does.
Devil's claw is the secondary storage root of Harpagophytum procumbens, and the marker constituent used for standardisation is the iridoid glycoside harpagoside.
Iridoid glycosides are intensely bitter, and that bitterness is the basis of the root's traditional use as a digestive bitter through reflex stimulation of gastric secretion.
The secondary tuber, not the primary root, carries the harpagoside; correct plant part is therefore part of the material specification, not a quality nicety.
Harpagoside is a glycoside, so it is largely deglycosylated by gut microbial enzymes before absorption; the circulating species are aglycone metabolites rather than the labelled marker itself.
Where Devil's Claw comes from.
The part used is the small storage tubers that hang off the main root of a southern African desert plant. They are dug up by hand, sliced, sun-dried, then either ground or soaked in water or alcohol to make a concentrated extract, which is tested for a marker compound called harpagoside.
Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.
The plant grows in the sandy soils of Namibia, Botswana and South Africa. Nearly all commercial supply is still wild-collected rather than cultivated, and harvesting is regulated under national permits and CITES Appendix II trade monitoring.
Collectors dig laterally to reach the secondary storage tubers and leave the primary root in place so the plant regrows. The primary root does not carry the marker constituents.
Tubers are sliced thin and sun-dried within a day or so of lifting, since the fresh tissue is water-rich and spoils quickly. Drying speed affects the surviving harpagoside.
Milled root is extracted with hot water or an ethanol and water mixture. Extraction pH and temperature are controlled because the iridoid glycoside degrades under acid.
The extract is filtered, concentrated under reduced pressure and dried, typically onto a carrier for free-flowing powder.
Lots are assayed by HPLC against harpagoside and blended to the declared percentage, most often 1.5 to 3 percent for extracts.
The forms it comes in.
The essence, in one line each.
- Two high-quality trials found daily doses standardized to 50 mg or 100 mg harpagoside eased short-term lower-back pain and reduced rescue-medication use more than placebo, with one trial showing it worked about as well as 12.5 mg rofecoxib.Meta-analysis. Gagnier et al., 2006 (Cochrane Database of Systematic Reviews). PMID 16625605 ↗
- In 122 adults with hip or knee joint wear, 2,610 mg per day of Harpagophytum powder reduced pain and functional limitation as much as 100 mg diacerhein over four months, and participants used significantly fewer analgesic and anti-inflammatory tablets.Randomised trial. Chantre et al., 2000 (Phytomedicine). PMID 11185727 ↗
- In an open 12-week study, an aqueous Devil's claw extract (50 mg harpagoside daily) lowered the total WOMAC joint index by about 23% in 75 adults with hip or knee joint wear, with improvement across the pain, stiffness and physical-function subscales.Cohort study. Wegener and Lupke, 2003 (Phytotherapy Research). PMID 14669250 ↗
- Adults with ongoing joint discomfort who took a supplement combining Harpagophytum procumbens with ginger reported less discomfort and easier joint movement over the supplementation period, with the result belonging to the combination rather than devil's claw alone.Randomised trial. González-Gross et al., 2021 (International Journal of Environmental Research and Public Health). PMID 34067240 ↗
- In a single-arm multicentre observation, adults taking a supplement containing devil's claw reported improved joint comfort and mobility, though without a control group the change cannot be separated from time and expectation.Cohort study. Puigdellívol Grifell et al., 2024 (Journal of Dietary Supplements). PMID 38180010 ↗
These are the studies our verdict leans on, chosen from the 254 we read for Devil's Claw. The full linked list is below.
The studies, linked.
2 sources behind our Devil's Claw verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialA Randomized, Double-blind, Placebo-controlled, Dose-ranging Two- Centre Study to Evaluate the Efficacy and Safety of Devil's Claw in the Treatment of Knee and Hip OsteoarthritisClinicalTrials.gov ↗PHASE2 · 67 participants · Terminated
- Clinical trialStudy to Establish the Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract in HumansClinicalTrials.gov ↗EARLY PHASE1 · Withdrawn
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 48 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Devil's Claw is, not how risky it is. A report is not proof Devil's Claw caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.